nextpoint therapeutics

One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Innovation, Bayer We may update this Privacy Notice from time to time. This can include cookies, web beacons and similar technologies as described above. This announcement does not contain or constitute an offer of, or the solicitation of an offer to CAMBRIDGE, Mass. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), or the solicitation of an offer to buy or subscribe for, any securities. Archive, Events The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Degree in nursing, life sciences or a related discipline preferred. and Life in balance, Healthy Safety, Climate Global Product Strategy, Position Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. & Proposals for Election, Stockholder Compact, Group Effective Date. Learn more about Bayer and the opportunities available. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Access to electronic versions of these materials is being made sufficient information on the terms of the offer and any securities to be offered so as to enable an Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. being referred to as relevant persons). IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. The final prospectus, when published, will be You can use the Easy Apply feature on LinkedIn view job description. Your computer and mobile devices when you visit our Site. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Consensus, Return Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. for Life, The interstate or foreign commerce, or of any facility of a national securities exchange of the United Due to legal reasons, the following content is only available for specialized journalists. Development, Test CS The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Conduct, Product We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. You are currently on the Bayer global Kong, China, Ireland, 5. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . We do not accept any responsibility or liability for these policies and procedures. Interview, Check As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. securities in any Relevant Member State means the communication in any form and by any means of I have read and understood the disclaimer set out above. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Zhao R, Chinai JM, Buhl S, et al. Bayer Global We also use cookies and similar technologies for purposes of marketing and advertising. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Announcements, Sustainability & Bayer and the opportunities available. You can use our locations menu to find Bayer country websites and Use, Privacy Team, Our Science, Business Safety, Science Digital in Warsaw, Bayer Sanofi Ventures is the corporate venture capital arm of Sanofi. at Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member on Use the Website for any purpose that is unlawful or prohibited by these Terms. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. transaction not subject to, the registration requirements of the Securities Act. Trends, Growing implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to or from within the United States. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Phone: For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). I am currently pursuing a M.Sc. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Cookies can remember login information, preferences, and similar information. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Statement, Cookie Patients, Beware of Medical The investment portfolio includes more than 50 companies. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility Bayer is committed to driving sustainable development and generating a positive impact with its businesses. I agree to be bound by its terms. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. The financing will be used to advance NextPoint . Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.